Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferons in relapsing remitting MS: a systematic review comments on a meta-analysis.

M Clanet1, M Cucheratt

  • 1Service de Neurologie, CHU Toulouse Purpan, Toulouse, France.

International MS Journal
|February 24, 2004
PubMed
Summary

Recombinant interferons show uncertain clinical effects beyond one year in relapsing-remitting multiple sclerosis (RRMS). Further long-term trials are necessary to confirm their effectiveness in managing RRMS.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis.

European journal of neurology·2018
Same author

Peripheral late reactivation of a previously typical monofocal Baló's concentric sclerosis lesion.

Multiple sclerosis (Houndmills, Basingstoke, England)·2015
Same author

[Cerebrotendinous xanthomatosis: a multicentric retrospective study of 15 adults, clinical and paraclinical typical and atypical aspects].

Revue neurologique·2014
Same author

[Implementation of a massive transfusion protocol in an emergency department].

Revue medicale de Liege·2014
Same author

A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort.

European journal of neurology·2013
Same author

Impact of intermittent catheterization on the quality of life of multiple sclerosis patients.

World journal of urology·2013

Area of Science:

  • Neurology
  • Immunology

Background:

  • Recombinant interferons are a major therapeutic class for relapsing-remitting multiple sclerosis (RRMS).
  • Recent systematic reviews question the long-term clinical efficacy of these treatments beyond one year.
  • The MS community requires clarity on the sustained benefits of interferon therapy.

Purpose of the Study:

  • To address the uncertainty surrounding the long-term effectiveness of recombinant interferons in RRMS.
  • To provide an explanation for patients and neurologists regarding the clinical utility of these therapies.

Main Methods:

  • Systematic review of major therapeutic recombinant interferon trials in RRMS.
  • Analysis of reported clinical effects beyond the one-year mark.

Main Results:

Related Experiment Videos

  • The clinical effect of recombinant interferons in RRMS beyond one year was found to be uncertain.
  • The need for new trials to assess long-term effectiveness was highlighted.

Conclusions:

  • The long-term effectiveness of recombinant interferons in RRMS requires further investigation through extended trials.
  • Patients and clinicians need a comprehensive understanding of treatment benefits beyond initial assessments.